论文部分内容阅读
目的探讨乳腺癌穿刺活检组织ER、PR和HER2免疫组化检测的准确性。方法将我院收治的乳腺癌患者行根治性手术,对术前穿刺活检组织的ER、PR和HER2免疫组化与术中切除的标本进行比较。结果 36例患者中,术前穿刺活检标本的ER阳性26例(72.22%)、PR阳性25例(69.44%)、HER2阳性19例(52.77%);术中切除标本ER阳性28例(77.78%)、PR阳性26例(72.22%),HER2阳性22例(61.11%);检测结果显示手术前后的一致率ER为91.67%,PR为91.67%,HER2为86.11%。结论乳腺癌穿刺活检组织ER、PR免疫组化结果与手术切除标本基本一致,而HER2免疫组化的一致率稍逊色,在选择手术方法时要综合考虑,术前相关免疫组化检测十分必要。
Objective To investigate the accuracy of immunohistochemical detection of ER, PR and HER2 in biopsies of breast cancer. Methods Radical surgery was performed in patients with breast cancer admitted to our hospital. The immunohistochemical staining of ER, PR and HER2 in the biopsy tissues before operation was compared with the resected specimens. Results Among the 36 patients, 26 (72.22%) were ER positive, PR positive 25 (69.44%) and HER2 positive 19 (52.77%) were detected by biopsy before operation, 28 were ER positive (77.78% ), PR positive in 26 cases (72.22%) and HER2 positive in 22 cases (61.11%). The results showed that the consistency rate before and after ER was 91.67%, PR was 91.67%, HER2 was 86.11%. Conclusion The immunohistochemical results of ER and PR in breast biopsy tissue are basically the same as those in surgical resection. However, the concordance rate of HER2 immunohistochemistry is less than that in the biopsy of breast cancer, so it is necessary to consider the preoperative immunohistochemistry in the selection of surgical methods.